Retrospective Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. May 15, 2024; 16(5): 1861-1868
Published online May 15, 2024. doi: 10.4251/wjgo.v16.i5.1861
Is sarcopenia effective on survival in patients with metastatic gastric cancer?
Ozlem Dogan, Hayriye Sahinli, Yakup Duzkopru, Tuba Akdag, Abdulkadir Kocanoglu
Ozlem Dogan, Department of Medical Oncology, Adıyaman University Training and Research Hospital, Adiyaman 02100, Turkey
Hayriye Sahinli, Yakup Duzkopru, Department of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, Turkey
Tuba Akdag, Department of Radiology, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara 06000, Turkey
Abdulkadir Kocanoglu, Department of Medical Oncology, Ankara Ataturk Sanatoryum Training and Research Hospital, Ankara 06170, Turkey
Author contributions: Dogan O took part in the planning, data collection, ethics committee application, and writing of the manuscript; Sahinli H contributed to the statistical analysis and writing of the data; Duzkopru Y contributed to the planning and data collection of the manuscript; Akdag T evaluated and measured radiology images; Kocanoglu A contributed to data collection.
Institutional review board statement: The study was reviewed and approved by the Health Sciences University Diskapi Yildirim Beyazit Training and Research Hospital Ethics Committee (Approval No. 119/05).
Informed consent statement: The institutional review board waived the need for informed consent due to the study’s retrospective methodology.
Conflict-of-interest statement: The authors declare having no conflicts of interest.
Data sharing statement: Raw data were generated at Health Sciences University Diskapi Training and Research Hospital. Derived data supporting the findings of this study are available from the corresponding author upon request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ozlem Dogan, PsyD, Staff Physician, Department of Medical Oncology, Adıyaman University Training and Research Hospital, No. 13 1164 Sk, Adiyaman 02100, Turkey. drozlemdogan@hotmail.com
Received: December 19, 2023
Peer-review started: December 19, 2023
First decision: December 28, 2023
Revised: January 16, 2024
Accepted: March 5, 2024
Article in press: March 5, 2024
Published online: May 15, 2024
Processing time: 142 Days and 1.7 Hours
Core Tip

Core Tip: In our study, the median survival of patients with sarcopenia was 2 mo, while it was 10 mo for those without sarcopenia and it was a statistically significant difference. Sarcopenia has an impact on the survival rates of individuals with solid tumors. If we can quickly identify sarcopenic patients through the Hounsfield units’ measurement at the time of diagnosis, contribute to survival by furnishing these patients with the requisite nutritional assistance before treatment.